Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis

Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis

(2022) Nishadh Sutaria et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Mechanistic insights into the antipruritic effects of lebrikizumab, an anti–IL-13 mAb

(2022) Yannick Miron et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis

(2022) Nishadh Sutaria et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments

(2022) Anthony Bewley et al.   Dermatology and Therapy

Itch intensity in prurigo nodularis is closely related with dermal interleukin‐31, oncostatin M, IL‐31 receptor alpha, and oncostatin M receptor beta

(2021) Takashi Hashimoto et al.   EXPERIMENTAL DERMATOLOGY

Circulating blood eosinophils as a biomarker for variable clinical presentation and therapeutic response in patients with chronic pruritus of unknown origin

(2021) Youkyung S. Roh et al.   Journal of Allergy and Clinical Immunology-In Practice

IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses

(2021) Youkyung S. Roh et al.   DRUGS

Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization

(2021) Micah Belzberg et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Interleukin-31 and Pruritic Skin

(2021) Masutaka Furue et al.   Journal of Clinical Medicine

Pruritus as a Distinctive Feature of Type 2 Inflammation

(2021) Simone Garcovich et al.   Vaccines

Latent Class Analysis Identification of Prurigo Nodularis Comorbidity Phenotypes

(2021) Shannon Wongvibulsin et al.   BRITISH JOURNAL OF DERMATOLOGY

Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans

(2021) Nishadh Sutaria et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Health-related quality of life and economic burden of prurigo nodularis

(2021) Katherine A. Whang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

(2020) Sonja Ständer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Periostin Activation of Integrin Receptors on Sensory Neurons Induces Allergic Itch

(2020) Santosh K. Mishra et al.   Cell Reports

Practical approaches for diagnosis and management of prurigo nodularis: US expert panel consensus

(2020) Sarina Elmariah et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response

(2020) Husein Husein-ElAhmed et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Association between prurigo nodularis and malignancy in middle-aged adults

(2019) Valerie A. Larson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IL-17A induces endothelin-1 expression through p38 pathway in prurigo nodularis

(2019) Lai-San Wong et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis patients

(2018) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis

(2012) Y. Yamaguchi et al.   BRITISH JOURNAL OF DERMATOLOGY

IL-5 and eosinophilia

(2008) Kiyoshi Takatsu et al.   CURRENT OPINION IN IMMUNOLOGY